ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,421 to 3,440 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
aQIV vs Comparator QIV: serious adverse events31 of 1,027

31 of 1,016

-0.0 points

-1.6 to 1.5

2,043NCT05044195

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Vaccine vs Placebo: Participant Dropout After Unblinding241 of 1,036

309 of 999

-7.7 points

-11.5 to -3.8

2,035NCT00865566

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Zoledronic Acid 4 mg Q4W vs Denosumab 120 mg Q4W: serious adverse events471 of 1,013

453 of 1,020

2.1 points

-2.2 to 6.4

2,033NCT00321464

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

PIIA: SAPIEN XT vs Control: SAVR: All-cause Death or Disabling Stroke to Two Years192 of 1,011

202 of 1,021

-0.8 points

-4.2 to 2.6

2,032NCT01314313

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

PIIA: SAPIEN XT - 2 Year vs Control: SAVR - 2 Year: deaths from any cause166 of 1,011

170 of 1,021

-0.2 points

-3.5 to 3.0

2,032NCT01314313

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

Lasmiditan 100mg vs Lasmiditan 200mg: Number of Participants With at Least 1 Treatment Emergent Adverse Event447 of 991

545 of 1,039

-7.3 points

-11.7 to -3.0

2,030NCT02565186

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

Lasmiditan 100mg vs Lasmiditan 200mg: serious adverse events29 of 991

36 of 1,039

-0.5 points

-2.1 to 1.0

2,030NCT02565186

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications During the Peri-PCI Period48 of 1,024

58 of 1,002

-1.1 points

-3.1 to 0.9

2,026NCT00790907

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Major Bleeding During the Peri-PCI Period14 of 1,024

12 of 1,002

0.2 points

-0.9 to 1.2

2,026NCT00790907

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Major Vascular Access Site Complications During the Peri-PCI Period33 of 1,024

43 of 1,002

-1.1 points

-2.8 to 0.6

2,026NCT00790907

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Minor Bleeding During the Peri-PCI Period7 of 1,024

17 of 1,002

-1.0 points

-2.1 to -0.1

2,026NCT00790907

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Composite of Major Bleeding During the Peri-PCI Period, With Death, MI, or TVR at Day 3059 of 1,024

39 of 1,002

1.9 points

-0.0 to 3.8

2,026NCT00790907

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

EVR+rCNI vs MPA+sCNI: Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation.276 of 1,014

152 of 1,012

12.2 points

8.7 to 15.7

2,026NCT01950819

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

EVR+rCNI vs MPA+sCNI: Incidence of Major Cardiovascular Events.66 of 1,014

86 of 1,012

-2.0 points

-4.3 to 0.3

2,026NCT01950819

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: deaths from any cause20 of 1,014

29 of 1,012

-0.9 points

-2.3 to 0.5

2,026NCT01950819

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

EVR+rCNI vs MPA+sCNI: Incidence of Malignancies.41 of 1,014

39 of 1,012

0.2 points

-1.5 to 1.9

2,026NCT01950819

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: serious adverse events593 of 1,014

613 of 1,012

-2.1 points

-6.4 to 2.2

2,026NCT01950819

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Intervention vs Control: deaths from any cause15 of 1,029

19 of 997

-0.4 points

-1.6 to 0.7

2,026NCT03679247

Electronic Tools to Increase Recognition and Improve Primary Care Management for Hypertension in Chronic Kidney Disease

Group 1: cHL vs Group 2: RRHL: deaths from any cause243 of 1,598

136 of 426

-16.7 points

-21.6 to -12.1

2,024NCT03327571

B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes

Group 1: cHL vs Group 2: RRHL: serious adverse events303 of 1,598

103 of 426

-5.2 points

-9.9 to -0.9

2,024NCT03327571

B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=172"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=172

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT05044195-sae",
        "title": "aQIV vs Comparator QIV: serious adverse events",
        "summary": "31 of 1027 against 31 of 1016; risk difference -0.0 points, 95% interval -1.6 to 1.5; NCT05044195, A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age",
        "record": "/library/comparisons/NCT05044195-sae",
        "nct_id": "NCT05044195",
        "kind": "serious-adverse-events",
        "participants": 2043,
        "risk_difference": {
          "value": -0.0003268061550728771,
          "lower": -0.015613059400811593,
          "upper": 0.014908878631297993
        },
        "group_1": "31 of 1,027",
        "group_2": "31 of 1,016",
        "difference": "-0.0 points",
        "interval": "-1.6 to 1.5",
        "trial_title": "A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age"
      },
      {
        "id": "NCT00865566-aa501b8e",
        "title": "Vaccine vs Placebo: Participant Dropout After Unblinding",
        "summary": "241 of 1036 against 309 of 999; risk difference -7.7 points, 95% interval -11.5 to -3.8; NCT00865566, Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men",
        "record": "/library/comparisons/NCT00865566-aa501b8e",
        "nct_id": "NCT00865566",
        "kind": "outcome",
        "participants": 2035,
        "risk_difference": {
          "value": -0.0766838266838267,
          "lower": -0.11504886213486186,
          "upper": -0.03808587053316391
        },
        "group_1": "241 of 1,036",
        "group_2": "309 of 999",
        "difference": "-7.7 points",
        "interval": "-11.5 to -3.8",
        "trial_title": "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=173",
  "request_id": "XgqJnzGAxtgoqLS8"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?